Medication info
Kratin Tablet 20mg (Rosuvastatin Calcium)

Kratin Tablet 20mg (Rosuvastatin Calcium)

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Daewoong Bio Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201602574 · Approved 2016.05.10 · Insurance code 694001080

Summary

Main use
Treatment of dyslipidemia; inhibition of atherosclerosis progression; prevention of cardiovascular disease
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of the day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased up to a maximum of 20 milligrams daily. 3. Elderly patients: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Assessment of renal function should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
Children's dosage
Ages 10 to 17 years: The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses greater than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or more. Under 10 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
Daewoong Bio Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia; inhibition of atherosclerosis progression; prevention of cardiovascular disease

  • Hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • primary dysbetalipoproteinemia
  • excess total cholesterol
  • excess LDL-cholesterol
  • excess Apo-B protein levels
  • risk factors for coronary heart disease
  • excess high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
View approved original text

This medication is used in those patients with primary hypercholesterolemia and mixed hyperlipidemia who are not adequately controlled with a diet and exercise. It is also used as an adjunct to diet in patients with homozygous familial hypercholesterolemia and helps to lower total cholesterol and LDL-cholesterol levels, delaying the progression of atherosclerosis. In some pediatric patients with heterozygous familial hypercholesterolemia, it is used as an adjunct to diet to reduce cholesterol and Apo-B protein levels. It can also assist patients with primary dysbetalipoproteinemia. Particularly, in men over the age of 50 and women over the age of 60 with certain cardiovascular disease risk factors, it contributes to risk reduction for stroke, myocardial infarction, and arterial revascularization. This medication is used primarily for the treatment of hyperlipidemia and reduction of cardiovascular disease risk.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of the day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased up to a maximum of 20 milligrams daily. 3. Elderly patients: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Assessment of renal function should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Children's dosage

Ages 10 to 17 years: The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses greater than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or more. Under 10 years of age: Safety and efficacy have not been established.

Precautions

This medication should not be used in certain patients. For instance, it should not be given to patients with an allergy to its components, those with severely impaired liver function, patients with muscle disorders, those taking cyclosporine, patients with severe renal impairment, and women who are pregnant or breastfeeding. Additionally, high-dose use is prohibited in patients at high risk for muscle disorders. As this medication contains lactose, it should not be administered to patients with certain genetic lactose intolerance. This medication can affect liver function; therefore, patients who consume alcohol excessively or have a history of liver disease should undergo repeat liver function tests before administration. Muscle-related side effects such as myalgia or myopathy may occur, so any symptoms of muscle pain or weakness should be reported to healthcare professionals immediately. Patients with renal impairment, hypothyroidism, or a history of genetic muscle disorders should be especially cautious. This medication may rarely cause serious skin reactions or liver damage; therefore, administration should be stopped immediately if symptoms such as rash or jaundice occur. Drug interactions may occur when used concurrently with other medications, so if you are taking other drugs, you must inform your healthcare provider. In particular, some antiviral agents, immunosuppressants, and antifungal drugs may increase the blood levels of this medication, raising the risk of muscle side effects. Women who are pregnant or of childbearing potential should employ appropriate contraception and should not use this medication during pregnancy. Breastfeeding should also be avoided while using this medication. In case of overdose, since there is no specific antidote, management is based on symptoms and monitoring liver function and muscle enzyme levels. Caution is advised as dizziness may occur while driving or operating machinery. This medication may show higher blood levels in Asians, therefore dosage adjustments may be necessary.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ophthalmoplegia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, drug-induced erythema multiforme, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disturbances, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, increased AST, arthralgia, fatigue, numbness, paresthesia, discomfort in the chest, loss of appetite, abdominal distension, abnormal liver function tests, syncope, generalized pain

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to protect it from air and moisture. It is advisable to maintain the storage temperature between 1 and 30 degrees Celsius to safely preserve the effectiveness of the medication.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.